Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
Phase 3
Completed
- Conditions
- Migraine
- Registration Number
- NCT00095004
- Lead Sponsor
- Organon and Co
- Brief Summary
The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 167
Inclusion Criteria
- Six month history of migraine; attacks typically mild when they begin with 1-4 migraine attacks per month.
Read More
Exclusion Criteria
- Heart disease
- High blood pressure
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percentage of patients who are pain free at 2 hours postdose Tolerability as measured by subjective adverse experience reporting
- Secondary Outcome Measures
Name Time Method Percentage of patients with 24 hour sustained pain freedom Percentage of patients requiring rescue medication between 2 & 24 hours Percentage of patients pain free at 30/45/60/90 minutes post dose Percentage of patients with associated symptoms at 2 hours Percentage of patients with functional disability at 2 hours